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Treatment of malnourished CAPD patients with an amino acid based
dialysate. Nineteen malnourished chronic peritoneal dialysis patients who
were ingesting a low protein intake underwent metabolic balance studies
to test whether a dialysate that contained amino acids would improve their
protein nutrition. Patients lived in the hospital for 35 days while they ate
a constant diet and underwent their usual regimen of continuous ambu-
latory peritoneal dialysis (CAPD). The first 15 days served as a Baseline
Phase. For the last 20 days, the usual dialysate was substituted with a
dialysate of essentially the same composition except that it contained 1.1%
essential and nonessential amino acids and no glucose. Patients received
one or two dialysate exchanges with amino acids each day depending on
the amount necessary to bring the individual's dietary protein plus
dialysate amino acid intake to 1.1 to 1.3 g/kg body weight/day. During
Baseline, patients were in neutral nitrogen balance; net protein anabolism
was positive, as determined from 15N-glycine studies. After commencing
intraperitoneal amino acid therapy, nitrogen balance became significantly
positive, there was a significant increase in net protein anabolism, the
fasting morning plasma amino acid pattern became more normal, and
serum total protein and transferrin concentrations rose. Patients generally
tolerated the treatment well, although some patients developed mild
metabolic acidemia. These findings indicate that a dialysate containing
amino acids may improve protein malnutrition in CAPD patients ingesting
low protein intakes.
Recent studies indicate that many adult patients undergoing
either maintenance hemodialysis or chronic peritoneal dialysis
show evidence for protein-calorie malnutrition [1—7]. The inci-
dence of malnutrition in chronic peritoneal dialysis patients is
reported to range from about 18 to 59% [4—71. Severe malnutri-
tion is reported to occur in 8 to 37% of patients [4—7].Although
many factors may engender malnutrition in maintenance perito-
neal dialysis patients, inadequate intake of protein and calories
appears to be an important cause. Protein and amino acid losses
in dialysate may intensify protein malnutrition in these patients [8,
9]. Since malnutrition may be an important risk factor for
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morbidity and mortality in chronic peritoneal dialysis patients [10,
11], this problem is of considerable clinical importance.
Several investigators have examined the nutritional benefits of
substituting amino acids for glucose in peritoneal dialysis solu-
tions [12—20]. This treatment should both augment the amino acid
intake and reduce the net amino acid losses of the patient, thereby
increasing the net intake of protein precursors. In most but not all
studies, the treatment with dialysate containing amino acids was
associated with improvement in nutritional indicators, including
increased serum proteins [12, 15, 18, 19], normalization of the
plasma amino acid profile [14, 18], increased nitrogen balance [14,
20], and weight gain [14, 19]. In a number of these studies,
malnutrition or low protein intake was not a requirement for
patient selection. Moreover, there was little or no attempt to
control the dietaiy nutrient intake of the patients before and
during the treatment with intraperitoneal amino acids. If low
nutrient intake was not a cause of malnutrition, dialysate with
amino acids might not be expected to improve nutritional status.
Also, the nitrogen balance data were obtained over very short
periods of time and sometimes by estimating total nitrogen intake
and output.
The present multicenter study was undertaken to assess the
nutritional and metabolic effects of an amino acid dialysis solution
in malnourished patients undergoing chronic peritoneal dialysis.
Each patient had a documented marginal or low protein intake
that was considered to be a cause of their malnutrition. During the
study, each patient was hospitalized for 35 days and received a
constant protein and energy diet in order to exclude the possibility
that a change in dietary intake might influence the metabolic
response during the study. After a 15 day Baseline Phase, patients
entered a Treatment Phase where one or two exchanges of
dialysate containing 1.1% amino acids were substituted for one or
two standard dialysates containing D-glucose. The results indicate
that treatment with one or two amino acid dialysis solutions each
day increased nitrogen balance, protein turnover and net protein
accrual, raised serum total protein and transferrin levels, and
tended to normalize several postabsorptive plasma amino acid
concentrations.
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Methods
Patients
This was a multicenter study involving 24 patients from the
Divisions of Nephrology from the following medical centers
(parentheses indicate the number of subjects who successfully
completed the study at each individual center): Boston University
(5), Harbor-UCLA Medical Center (5), University of Michigan
(4), Karolinska Institute (3), and University of Iowa (2). Five
patients were discontinued from the study for the following
reasons: two episodes of peritonitis occurred during the Baseline
Phase, and a third occurred on the third day of treatment with
amino acid dialysate. One patient was discharged from the study
during the Baseline Phase because of generalized debility prevent-
ing compliance to the protocol. The fifth patient was discontinued
from the study on the third day of the Treatment Phase because
of an incarcerated hernia associated with nausea. Data from the
remaining 19 patients who completed the study comprise the body
of this report.
The major patient eligibility criteria for participation in the
study included the following: a diagnosis of protein malnutrition
based on the following criteria: (a) evidence for muscle wasting by
clinical appraisal or a decrease in mid-arm muscle circumference;
(b) a body weight of 90% or less of desirable body weight or a
serum albumin of 4.0 gIdl or less in men and 3.7 g/dl or lower in
women; and (c) an inadequate dietary protein intake prior to
entering the study (that is, a protein intake of 1.0 g/kg actual body
weight per day or less). Desirable body weight is determined as
the median weight of individuals of the same age range, gender,
height and frame size as the patient as determined from the 1983
Metropolitan Life actuarial tables [21]. Dietary intake was deter-
mined from a five day dietary diary kept by the patient and a
dietary interview with a dietitian during the screening period
before the patient was accepted into the study. Other inclusion
criteria for the study were treatment with continuous ambulatory
peritoneal dialysis (CAPD) or continuous cyclic peritoneal dialy-
sis for at least four months and ages 18 to 75 years. Patients were
excluded if their renal creatinine clearance was greater than 5.0
ml/min or if they had insulin dependent diabetes mellitus, any
illness requiring hospitalization within 30 days, one episode of
peritonitis within the past month, more than one episode of
peritonitis in the past six months, the presence of cancer except
basal cell carcinoma, severe liver, lung or heart failure, vasculitis,
psychosis, or if they were not clinically stable. This study was
approved by the institutional review board from each participating
clinical center. All patients gave informed written consent before
commencing the study.
Upon entering the study, patients lived in a clinical research
center for 35 days. An exception were the three subjects studied in
Sweden who lived in a general nephrology ward but whose meals
were prepared in a kitchen modified for metabolic balance
studies. Throughout the 35 day study, patients were fed a constant
diet that was calculated to provide 0.80 g protein (allowable range,
0.70 to 0.90)/kg actual body weight/day and an energy intake
estimated to meet the patient's energy requirements, 28 3
kcallkglday (range, 23 to 38). For each individual patient, the daily
intake of both energy and protein was divided into portions of
approximately 2/8, 2/8, 3/8 and 1/8 for consumption at breakfast,
lunch, supper and the snack. Dietary fat, sodium and potassium
intake was designed to be similar to the patient's prestudy intake.
The diets were prepared using metabolic kitchen protocols that
have been employed in previous studies [22]. Any changes in food
intake were strongly discouraged after the first three to four days
of the study. All patients were given one tablet per day of a
multivitamin supplement. Many patients also received other med-
icines typically prescribed for chronic dialysis patients including
antihypertensive medications, erythropoietin, phosphate binders,
and various other agents. No patient was started or stopped on
erythropoietin therapy or any other anabolic or catabolic medi-
cines (for example, corticosteroids) during or within several weeks
before commencing the study.
The first 15 days of the study were considered a Baseline Phase
during which each patient underwent a CAPD regimen similar to
his/her prestudy treatment. Eighteen patients received four dia-
lysate exchanges per day and one patient received five exchanges
daily. For the four daily exchanges, the instillation of fresh
dialysate was generally started at 8:00 a.m. (after the morning
blood drawing), 1:00 p.m., 5:00 p.m., and 11:00 p.m. Drainage of
dialysate was initiated about 15 minutes before instillation except
for the morning drainage which was begun at 7:30 a.m. to allow
time for weighing the patient and for blood drawing before the
8:00 a.m. instillation. Dianeal® 1.5%, 2.5% and 4.25%, (Baxter
Healthcare, Deerfield, IL, USA) were the dialysate solutions used
during the study (anhydrous glucose concentrations; 1.36, 2.27,
and 3.86 g/dl, respectively). Electrolyte composition of Dianeal®
(in mEq/liter) was sodium 132, calcium 3.5, magnesium 0.5,
chloride 96, and lactate 40. Fifteen patients used two liter bags for
all exchanges throughout the study; three individuals used 1.5 liter
exchanges for Dianeal® and 2.0 liter exchanges for the amino acid
dialysate solutions; and one patient used 1.5 liter bags exclusively
(including the dialysate with amino acids) during the study.
During the Treatment Phase, from days 16 to 35, patients
continued to undergo the same dietary and dialysis regimen
except that each day the patients received one or two dialysate
exchanges containing 1.1% amino acids and no glucose instead of
one or two of the regular 1.5% dextrose dialysate solutions. The
number of exchanges with amino acids that patients were given
was calculated so as to provide a total daily dietary protein plus
dialysate amino acid intake of 1.1 to 1.3 g/kg/day (assuming
absorption of about 80% of the instilled amino acids [15]), which
is similar to previously recommended protein intakes for CAPD
patients [22]. All patients received the dialysate with 1.1% amino
acids at the 8:00 a.m. exchange. The second amino acid exchange,
which was given to nine patients, was instilled at 5:00 p.m. Thus,
both amino acid exchanges were administered when patients were
in the postprandial state. Intraperitoneal amino acid treatment
was reduced from two to one exchange per day if the serum urea
nitrogen (SUN) rose to 112 mg/dl (40 mmol) or greater or if
uremic symptoms developed.
The composition of the dialysate with 1.1% amino acids was as
follows: amino acids (in mg/dl) histidine 71, isoleucine 85, methi-
onine 85, leucine 102, lysine 76 (added as 95 mg of the hydro-
chloride salt), phenylalanine 57, threonine 65, tryptophan 27,
valine 139, tyrosine 30, alanine 95, arginine 107, glycine 51,
proline 59, and serine 51. Electrolyte composition was the same as
with the Dianeal® solution except for the chloride concentration
which was 105 mEq/liter with the amino acid dialysate. The
calculated osmolarity was 365, and the pH was approximately 6.2.
Nitrogen balances were measured continuously in each patient
from days 6 through 15 of the Baseline Phase and from days 21
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through 35 of the Treatment Phase, using previously described
techniques [22]. Total nitrogen was measured in duplicate 24 hour
diets, at least five times during the study in each patient, in each
24 hour pooi of dialysate outflow, in urine collected daily or, for
oliguric patients with less than 500 ml urine output per day, in five
day urine pools, and in feces collected during the same five day
pools. Nitrogen balances were calculated for each of the five day
collection periods and were adjusted for changes in body urea
nitrogen as previously described [23].
Blood for measurement of serum urea, creatinine, and albumin
was obtained in the postabsorptive state after an overnight fast
between 7:45 and 8:00 a.m. at the beginning of days 1, 6, 11, 16, 21,
26, 31 and at the end of day 35 (that is, the beginning of day 36).
Serum total protein, transferrin, potassium, phosphorus and
HDL, LDL, and VLDL cholesterol were obtained for measure-
ment at the beginning of days 1, 16, and 36. Blood for plasma
amino acid analyses was drawn after an overnight fast between
7:45 and 8:00 a.m. at the beginning of days 1, 16, 26 and 36.
Arterialized venous blood pH and pCO2 were determined in seven
patients on days 5, 10, 25 and 33.
The blood for amino acid analyses was collected in tubes
containing dry heparin and was centrifuged immediately at 2,300
g for 15 minutes at 4°C. One milliliter of the supernatant was
pipetted off, taking care not to disturb the buffy coat, and added
to 45 mg of crystalline sulfosalicylic acid. After mixing, the
preparation was centrifuged for 15 minutes. The supernatant was
quickly pipetted into another tube and frozen at —60 to —70°C
until analyzed. The amino acid analyses were usually performed
within one month of obtaining the plasma. For collection of
arterialized venous blood, the blood was obtained from the
antecubital vein before the first morning exchange. The arm was
first wrapped in hot towels to increase blood flow. Blood was
drawn without using a tourniquet using anaerobic techniques.
Starting on days 8 and 26, patients underwent measurements of
total body protein turnover as described by Fern et al [24]. The
foregoing method was modified in that both pooled 24-hour
dialysate outflow and urine (if patients made urine) were collected
daily for longer periods, from days 6 to 15 and Days 24 to 33
because of the below normal urea clearances of our patients. For
each turnover study, after an overnight fast, patients ingested 5
mg/kg body weight of 15N-glycine 99 atom % (Merck and Co.
Inc./Isotopes, Quebec, Canada) before breakfast. The purity of
the 15N-glycine content of the isotope ingested was confirmed by
mass spectroscopic and total nitrogen analyses. Calculation of
protein synthesis, degradation and flux was performed as previ-
ously described [24], except that the '5N enrichment in total
nitrogen was measured and the results in dialysate and urine were
pooled.
Serum albumin and transferrin were measured in samples from
all five centers in a central laboratory at SmithKline Bio-Science
Laboratories (Van Nuys, CA, USA). Albumin was assayed by the
bromcresol green method and transferrin by nephelometry.
Plasma amino acids were determined with a Beckman Model 6300
Amino Acid Analyzer using a lithium buffer system in a Central
Amino Acid Laboratory (University of Iowa, L. Stegink, Direc-
tor). Total nitrogen was measured by pyrochemiluminescence
with an Antek Nitrogen Analyzer Model 401 (Antek Instruments,
Inc., Houston, TX, USA) in the Metabolic Laboratory, Critical
Care Diagnostic Service, Department of Surgery, University of
Michigan (Ann Arbor, MI, USA, R, Dechert, Director). 15N was
Table 1. Characteristics of patients
Total Male Female
Number of patients 19 14 5
Age,years 54 13° 57 11 47 15
Body weight, kg 68 12 69 12 63 10
Height, cm
Relative body weight, %b
171 9
91 13
172 10
92 13
168 6
90 11
Race, ethnic background
Asian 1 1 0
Afro-American 4 1 3
Caucasian 13 11 2
Hispanic 1 1 0
Duration of CAPD, years 2.3 2.3
(0.4—8.8)°
2.6 2.5
(0.7—8.8)
1.3 0.7
(0.4—2.3)
Prestudy dietary intake
Protein, g/kg/dayd
Energy, kcal/kg/dayde
0.91 0.12
24.9 5.7
0.88 0.12
24.3 5.9
0.98 0.08
26.7 5.4
Creatinine clearance, mI/mm 2.0 1.8
(0.0—5.0)
1.9 2.0
(0.0—5.0)
2.2 1.5
(0.0—4.0)
° Mean standard deviation; b (Current body weight/median Metro-
politan Life body weight for person of same gender, height, and frame
size) x 100%; C Parentheses indicate range of values; d Calculated from 5
day dietary diaries and interviews; ° Refers to intake from diet, and not
dialysate.
measured at the Mass Spectrometry Resource (Washington Uni-
versity, St. Louis, MO, USA) using a Nuclide 3-60 Isotope Ratio
Mass Spectrometer. Serum urea nitrogen, creatinine, total pro-
tein, lipids, lipoproteins, blood pH and pCO2, and other chemis-
tries were determined in the hospital laboratory at each partici-
pating center.
Statistics
Data were analyzed by analysis of variance (ANOVA) and
paired t-tests. Statistical significance was evaluated by the paired
t-test if the data were normally distributed and by the signed rank
test if the data were not normally distributed. The nitrogen
balance data were analyzed by a repeated measures multivariable
ANOVA. Since a significant time versus treatment interaction was
observed, paired t-tests were performed comparing days 6 through
10 to days 21 through 25, days 11 through 15 to days 26 through
30 and also the averages of the two control periods to the three
treatment periods. Data are expressed as mean standard
deviation.
Results
Characteristics of the 19 patients are shown in Tables 1 and 2.
As is apparent from their relative body weight, serum proteins and
dietary protein and energy intake, both protein and calorie
malnutrition were present in many patients. Fourteen patients
had a clinical appraisal of muscle wasting; midarm muscle circum-
ference (MAMC) was in the 25th percentile or lower in 14
patients; relative body weight (RBW) was 86% or lower in 11
patients; and the serum albumin concentration was 3.6 gldl or
lower in 16 subjects (range of serum albumin in 19 patients, 2.3 to
3.9 g/dl). Eight patients had a clinical appraisal of muscle wasting,
a MAMC in the 25th percentile or lower, a RBW of 86% or lower,
and a serum albumin of 3.6 g/dl or lower. Five patients showed
three of these four characteristics, five patients displayed two of
these characteristics, and one patient showed one characteristic.
Renal failure was caused by idiopathic glomerulonephritis in nine
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Table 2. Serum chemistries during the course of study
Onset of
Baseline
(Day 0)C
End of
Baseline
(Day 16)b
End of
treatment phase
(Day 36)C
P values
Day 16 vs.
Day 0
Day 36 vs.
Day 16
Urea nitrogen, mg/dl 60 16 49 12 77 22 0.0001 0.0001
Urea, mmol/liter 21 6 17 4 27 8
Creatinine, mg/dl 11.5 3.4 10.8 3.1 10.8 3.0 0.016 NS
mmol/liter 1017 301 955 274 955 265
Potassium, mEq/liter 4.1 0.4 4.2 0.7 3.9 0.6 NS 0.031
Phosphorus, mg/dl 5.6 1.4 4.8 1.4 3.8 1.7 0.017 0.0061
mmol/liter 1.8 0.5 1.5 0.5 1.2 0.5
Calcium, mg/dl 9.4 0.8 9.7 1.0 9.8 0.8 NS NS
mmol/liter 2.4 0.2 2.4 0.2 2.5 0.2
Alkaline phosphatase, U/liter 114 59 123 59 136 81 NS NS
CO2 combining power, niEq/liter 24.8 3.4 25.3 2.0 21.3 3.4 NS 0.0001
Albumin, g/dl 3.18 0.44 3.19 0.41 3.34 0.43 NS NS (0.063)
Transferrin, mg/dl 213 60 225 60 249 72 NS 0.022
Total protein, g/dl 5.89 0.57 5.97 0.50 6.27 0.76 NS 0.033
Triglycerides, mg/dl 160 101 151 68 174 92 NS 0.023
Total cholesterol, mg/dl 203 59 196 60 196 51 NS NS
HDL cholesterol, mg/dl 41 13 44 14 40 9 NS 0.0065
LDL cholesterol 126 48 122 51 122 45 NS NS
Apolipoprotein B, mg/dl 92 42 84 35 90 41 NS NS
a Blood obtained before breakfast at the beginning of the first day of study; b Bloodobtained before breakfast on day 16 (prior to first exchange with
amino acid dialysate); C Blood obtained before breakfast on day 36 (last day of study).
patients, diabetes mellitus in two patients, hypertensive nephro-
sclerosis in two patients, and lupus nephritis, interstitial nephritis,
polycystic kidney disease, Alport's syndrome, congenital hypoplas-
tic kidneys, and unknown etiology each in one patient. The patient
with lupus nephritis manifested no systemic activity at the time of
the study. Seven of the 19 patients were anuric; the creatininc
clearances in the other 12 patients averaged 3.0 1.4 ml/min
(range, 0.1 to 5.0). Kt/Vurea during the last eight days of the
Baseline and Treatment Phases was not different and averaged
1.53 0.36 and 1.61 0.46, respectively.
During the Baseline Phase there was a significant fall in serum
urea and creatinine (Fig. 1, Table 2), which may indicate that the
patients' hospital protein diet was lower than their prestudy intake
or that in the hospital they were more compliant to the dialysis
regimen. After commencing the intraperitoneal amino acid treat-
ment, serum urea rose rapidly, but serum creatinine did not
change. Serum calcium, alkaline phosphatase, total cholesterol,
LDL cholesterol and apolipoprotein B levels did not change
during the study (Table 2). Serum potassium (P = 0.031) and
HDL cholesterol (P < 0.01) fell slightly during the treatment
period. On the other hand, serum phosphorus fell progressively,
from 5.6 mg/dl at the onset of study to 3.8 mg/dl on Day 36. Also,
serum triglycerides rose from 151 68 to 174 92 (P = 0.023)
during the Treatment Phase (Table 2).
Serum albumin, transferrin and total protein did not change
during Baseline (Table 2, Fig. 2). After institution of dialysate
with amino acids, serum transferrin and total protein rose signif-
icantly, whereas serum albumin did not change (P = 0.063).
Plasma amino acids obtained before breakfast after an over-
night fast are shown in Table 3. Fasting plasma amino acids,
obtained from normal men and women from two separate labo-
ratories are shown for comparison. Median ages (and sample
sizes) of the subjects in these two populations were 25 years (N =
12) (University of Iowa Central Amino Acid Laboratory) and 50
years (range, 32 to 67; N = 29) [25], respectively. Since the
specimens from normal individuals were not obtained during the
present study and only one of the groups of normal subjects was
analyzed in the laboratory used in the present study, no statistical
comparisons between the normal values and the peritoneal dial-
ysis patients were performed.
At the end of Baseline (day 16), as compared to the day of onset
of the study (day 0), there was a significant increase in the
postabsorptive plasma total essential amino acids, total nonessen-
tial amino acids, and total amino acids which persisted throughout
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Fig. 1. Serum urea nitrogen (SUN) and serum creatinine in 19 CAPD
patients during the Baseline Phase (Days 0 to 16) and during Treatment
(Days 16 to 36) with a dialysate that contained amino acids, Circles and
brackets indicate the mean standard deviation. Symbols are: (•1 SUN;
(0) serum creatinine.
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the Treatment Phase. However, only three individual amino acids
increased significantly, and ornithine fell slightly at day 16 as
compared to day 0. During dialysis with amino acids, at both days
26 and 35, plasma total essential and total amino acids were
significantly greater than the values both at the onset of the study
(day 0) and at the end of Baseline (day 16). Plasma total
nonessential amino acids were not different during the Treatment
Phase as compared to the end of Baseline. Many individual amino
acids were significantly increased during the Treatment Phase as
compared to either the beginning or the end of the Baseline Phase
(Table 3). No amino acid was significantly lower during the
Treatment Phase than at the beginning of Baseline (day 0), and
only plasma taurine was significantly lower at day 26 or 35 as
compared to day 16. Virtually all of the increases in the plasma
amino acids that occurred during dialysis with amino acids were
present at day 26. Only plasma cystine was significantly higher and
taurine significantly lower at day 35 as compared to day 26.
The nitrogen balance data are shown in Table 4. Dietary
nitrogen intake averaged 8.45 g/day (range 5.8 to 11.0 g/day),
which is equivalent to 52.8 g protein/day or 0.80 0.09 g
protein/kg body wt/day. Some patients lost a small amount of
dietary nitrogen as emesis or uneaten food (Table 4); these losses
appeared to increase slightly after the intraperitoneal amino acids
were initiated. During the Treatment Phase, the nitrogen intake
increased by 47.5 15% due to the instillation of intraperitoneal
amino acids. The major route of nitrogen output was dialysate,
which increased by approximately 50% with the institution of
intraperitoneal amino acids. There was a trend for urine nitrogen
to increase slightly when the dialysate with amino acids was
instituted (1.5 1.3 vs. 1.3 1.1 g N/day in the Baseline Phase,
P = 0.083). On the other hand, there was no change in fecal
nitrogen output during the study.
During the last 10 days of the Baseline Phase, nitrogen balance,
adjusted for changes in body urea nitrogen, was similar during the
two balance periods, indicating that the patients had essentially
attained a steady state. Nitrogen balance was not different from
zero during these two periods. After intraperitoneal amino acids
were initiated, nitrogen balance became strongly positive and
remained positive for the duration of the study. Although nitrogen
balance tended to become less positive with time during the
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Treatment Phase, it remained significantly greater than zero
during each of the three balance periods (Table 4). It may be
estimated that between 0.50 and 1.0 g of nitrogen was lost each
day from the body from unmeasured sources including respira-
tion, growth of integumentary structures (epidermis, nails, hair),
sweat, flatus and the regeneration of protein and amino acids lost
from blood drawn [26]. If either of these amounts of nitrogen are
added to the total nitrogen output, the average nitrogen balance
would still not differ from zero during each of the two balance
periods in the Baseline Phase and would still be significantly
positive during each of the three balance periods in the Treatment
Phase.
Nitrogen balances were significantly more positive during Pe-
riod 5 as compared to Period 2 (P < 0.001), during Period 6 as
compared to Period 3 (P < 0.006), and with the average of the
three Treatment Phase periods (5 to 7) (+1.71 2.40 g/day) as
compared to the mean of the two Baseline Phase periods (2 and
3) (+ 0.50 1.85 g/day) (Treatment vs. Baseline, P < 0.001, Table
4). Nitrogen balance, when expressed per kg body weight and
averaged for all of the periods of each phase of the study, was also
significantly positive during Treatment (+0.0405 0.0520 g/kg/
day, P < 0.01) but not during Baseline (+0.0092 0.0270
g/kg/day) and was significantly more positive during Treatment as
compared to Baseline (P = 0.001).
The protein turnover data, calculated from the '5N-glycine
studies, are shown in Table 5. Data are available from 16 patients
who were each studied twice, once during Baseline and once
during Treatment. Total body protein flux tended to increase
during the Treatment Phase. There was no significant difference
during Treatment as compared to Baseline with regard to protein
synthesis or degradation. Protein balance, calculated as total body
protein synthesis minus degradation, was positive in both the
Baseline Phase (0.24 0.18 g protein/kg/day, P < 0.001) and with
intraperitoneal amino acids (0.35 0.23, P < 0.001). However,
net protein anabolism was significantly more positive during the
Treatment Phase than during Baseline (Treatment vs. Baseline, P
<0.001).
Unlike the nitrogen balances measured in all patients (Table 4),
the nitrogen balances depicted in Table 5 were significantly
400.
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l?ig. 2. Serum transfenin and total protein
concentrations in 19 CAPD patients at the
beginning (Day 0) and end (Day 16) of the
Baseline Phase and at the beginning (Day 16)
and end (Day 36) of the Treatment with a
dialysate that contained amino acids. Brackets
indicate the mean value plus one standard
deviation.
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Table 3. Pre-exchange morning fasting plasma amino acids"
Onset of Baseline
DayO"
End of Baseline
Day 16
Dialysis with 1.1% amino acids Normal values
Day 26 Day 36 N = 12" N = 29"
Essential
Histidine
Isoleucine
64 l3
54±14
64 10
57±14
76 14"°60±10
75 13'"'
56±11
79 19
78±27
88 10
64±16
Leucine 79±24 84±19 89±18' 89±21 129±36 127±27
Lysine 139 32 159 34" 173 391m 174 3iI 175 45 197 38
Methionine 20±4 23 10 22±4 23 33±6 28±5
Phenylalanine
Threonine
52±18
107 37
55 17
116 35
54 21
132 36"'
56 16
136 4O5
49 8
155 51
56 9
155 41
Valine 133 34 138 29 187 30"° 186 42"° 212 74 232 51
Total essential5 647 137 683 96' 781 81"' 794 114" 966 211 945 150
Semi-essential
Cystine 57±23 56 20 63 20° 69± 23"°" 45 8 61 10
Tyrosine 33±9 34±11 35±12 34±8 55±13 62±13
Non-essential
Aminobutyrate
Alanine
6±3
345 122
7±5
394 136"
11±4"
402 128"
10±6
414 155"
19±8
395 77
NA
433 116
Arginine 74 23 80 21 95 23" 93 19" 98 19 99 22
Asparagine 41±10 44±11 44±11 45±10' 49±18 48±13
AsparticAcid
Citrulline
14±7
88 29
13±5
89 26
16±6
98 26"
14±7
98 29"'
13±1
29 10
6±3
39 12
GlutamicAcid 43±25 50±20 40±19 46±26 37±14 46±22
Glutamine 651 94 671 135 689 123 660 92 540 90 480 133
Glycine 304 98 330 110 288 102 318 119 240 53 265 118
Hydroxyproline 37±14 36±11 33±13 35±13 17±9 16±13
Ornithine 62±19 52±12" 62±18m 59±15"' 64±24 66±28
Proline 187 70 186 44 203 47m 205 54" 187 54 210 65
Serine 67±14 68±18 71±14 71±12 110±28 108±24
Taurine 47 17 67 30" 55 23" 45 20°" 47 10 48±18
Total nonessential" 1773 324 1876 323 1885 274 1911 3S7 1707 231 1850 378
Total amino acids 2510 393 2649 368" 2766 312' 2808 4l8.m 2673 222 2933 514
"Blood was drawn before breakfast after an overnight fast several minutes after the abdomen was drained of dialysate and before the early morning
dialysate infusion; b Before breakfast at the beginning of the first day of study; "Normal data from the Central Amino Acid Laboratory, University of
Iowa (used by permission); d Normal data from the Central Amino Acid Laboratory, Harbor-UCLA Medical Center [25]; "Mean standard deviation
(gmol/liter); Number of patients was 18 on Days 0 and 36 and 19 on Days 16 and 26, Statistical comparisons were made on paired samples for the
18 patients in whom data were obtained for all 4 days; Calculated as the sum of histidine, isoleucine, leucine, lysine, methionine, phenylalanine,
threonine, and valine; "Calculated as the sum of alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine, and
taurine; 'Calculated as the sum of total essential amino acids, total nonessential amino acids, cystine, and tyrosine; ,,l',t Differs from Day 0, P C 0.05,
P < 0.01, P < 0.001, respectively; m,n,o Differs from Day 16, P C 0.05, P C 0.01, P C 0.001, respectively; "Differs from Day 26, P C 0.05.
positive during Baseline as well as during Treatment. This appar-
ent discrepancy may reflect the fact that only 16 of the 19 patients
underwent the protein turnover studies, and the nitrogen balances
data were only analyzed for eight days with each study. Moreover,
if balances are adjusted for estimated unmeasured nitrogen losses
of either 0.5 or 1.0 glday [26], nitrogen balances would still be
neutral during Baseline and significantly positive during Treat-
ment. Also, in the data shown in Table 5, nitrogen balance during
Treatment continued to be significantly more positive than during
Baseline.
Serum carbon dioxide combining power remained stable during
Baseline (Table 2). It then decreased significantly from 25.2 2.0
mEqlliter at the end of Baseline to 21.3 3.4 on Day 35 (Day 35
vs. Day 16, P < 0.001). This fall in serum carbon dioxide
combining power during dialysis with amino acids became appar-
ent after several patients had completed this clinical trial. Conse-
quently, in seven of the patients who entered the program after
this trend was observed, arterialized venous blood pH and pCO2
were measured four times (Fig. 3). The arterialized venous blood
pH and pCO2 fell slightly but significantly after commencing
dialysis with amino acids. The blood pH decreased from 7.40
0.03 on both days 5 and 10 to 7.36 0.04 on day 25 and 7.35
0.04 on day 33. On these four days, the pCO2 was 44.6 5.7, 44.8
3.4, 40.3 6.1 and 38.1 7.0 mm Hg, respectively.
In general, dialysis with the amino acid solution was well
tolerated. Of the 19 patients who completed the study, three
patients had nausea during the Baseline Phase with glucose
dialysate and two patients vomited. By contrast, five patients had
episodes of nausea during the Treatment Phase, and two patients
vomited during treatment with amino acids. One patient receiving
two exchanges per day experienced nausea without emesis on day
20 only (Treatment Phase) that was thought to be caused by
uremia; his treatment was not changed because his symptoms
abated. Only one of the nine patients that received two amino acid
dialysate exchanges per day was unable to tolerate this regimen.
She had eight episodes of nausea and vomiting during treatment
with intraperitoneal amino acids. On day 24 her SUN was 102
mg/dl, and her regimen was reduced from two amino acid
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Table 4. Nitrogen balance data in 19 malnourished CAPD patients (g N/day)
N intake g/day
N output g/day
Period
.Emesis or
uneaten Total i.\ Body Total N Balance
Period days Diet food Dialysate intakea Dialysate Urine" Feces urea NC output'1 g/daye
Baseline
Phase
2 6—10 8.47 l.3O 0.15 0.49 0 8.32 1.01 6.00 1.59 0.83 1.03 1.17 0.49 —0.05 0.35 7.95 1.94 +0.37 1.83
3 11—15 8.34 1.24 0.02 0.10 0 8.32 1.01 5.90 1.53 0.89 1.16 1.05 0.35 —0.18 0.50 7.66 2.09 +0.62 1.85
Mean +0.50 1.85
Treatment
Phase
5 21—25 8.34 1.19 0.06 0.19 4.92 1.59 13.19 2.32 8.31 2.16 0.95 1.17 1.11 0.51 +0.66 0.53 11.01 2.82 +2.15 2•35g,h
6 26—30 8.30 1.16 0.09 0.21 4.87 1.55 13.09 2.24 8.95 2.57 1.04 1.35 0.97 0.47 +0.38 0.38 11.34 3.00 + 1.61 2.42
7 31—35 8.16 1.27 0.26 0.53 4.73 1.56 12.63 2.31 9.03 2.73 1.06 1.39 1.15 0.46 —0.01 0.49 11.23 3.06 + 1.38 2.46
Mean + 1.71 240g,j
Calculated as the sum of diet and dialysate nitrogen minus emesis nitrogen; b Average values, some patients were anuric; c An increase and decrease
in body urea nitrogen is indicated by a plus and minus sign, respectively; "Calculated as the sum of dialysate, urine, feces and change in body urea
nitrogen; C Calculated as total intake minus total output of nitrogen; 'Mean standard deviation; Significantly different from zero, P < 0.001;hSignificantly different from nitrogen balance in period 2, P < 0.001; 'Significantly different from nitrogen balance in period 3, P < 0.001; Mean of
nitrogen balances in periods 5, 6, and 7 is significantly different from mean of balances in period 2 and 3, P < 0.001.
Table 5. Protein turnover before and during treatment with intraperitoneal amino acids"
Patient
No.
Body weight
kg
N balance"
g/kg/day Flux
Protein metabolism, g protein/kg/day
Synthesis Degradation Net anabolism
Baseline Phase 16 68.7 118d +0.022 0.028" 2.80 0.06 2.25 0.59 2.01 0.65 +0.24 O.l8
Treatment Phase 16 69.0 12.0 +0.040 0.035 3.29 1.01 2.49 0.97 2.14 1.00 +0.35 O.23
P values NS P = 0.002 NS (P = 0.063) NS NS P = 0.001
(Treatment vs.
Baseline5)
"Data collected during Days 845 of Baseline Phase and during Days 26 to 33 of Treatment Phase; b Weight on day that 15N-glycine was ingested;
C Refers to N balance measurements during the period of the protein turnover studies; " Mean standard deviation; "Significantly different from zero,
P < 0.01; Significantly different from zero, P < 0.001; gP values determined by the paired t-test.
exchanges per day to one. Her SUN declined to 92 mg/dI by Day
26 and to 82 mg/dl by Day 36. Nausea and vomiting slowly abated
after she began one exchange with amino acids per day.
Discussion
The results of this study indicate that chronic peritoneal dialysis
patients who have protein or protein calorie malnutrition and are
ingesting a low protein diet develop positive protein balance when
they receive dialysate containing amino acids. The evidence that
intraperitoneal amino acids enhance their anabolic status includes
a significant increase in nitrogen balance, greater net protein
anabolism, as determined by '5N-glycine turnover studies, and an
increase in serum transferrin and total protein concentrations.
Serum albumin levels also tended to rise with the intraperitoneal
amino acids, but the increase was not statistically significant (P <
0.07). There was an increase in fasting plasma total essential and
total amino acids as well as of a number of individual amino acids.
The rise was particularly evident for the essential amino acids
(Table 3).
Other researchers have investigated the nutritional benefits of
peritoneal dialysate containing amino acids. In several studies, a
significant increase in serum albumin or transferrin [12, 15, 18,
19], estimated nitrogen balance [14, 20], total body nitrogen [121,
or body weight [14, 19] was reported. On the other hand, some
studies showed no significant improvement in these nutritional
parameters [17], and in a number of studies not all nutritional
parameters increased, Moreover, in one of the two studies
showing a rise in serum albumin during the treatment with amino
acids in peritoneal dialysate, it was not sustained [18]. Interpre-
tation of these results is complicated by the fact that simultaneous,
randomized control groups were generally not used, normal
nutritional status was usually not a patient exclusion criterion, the
sample sizes were small, and dietary nutrient intake often was not
controlled or monitored. In the present study, although a separate
group of control patients was not used, the abrupt increase in the
anabolic status of the patients after Baseline, when treatment with
dialysate containing amino acids was inaugurated, provides strong
evidence that the enhanced protein balance of the patients was
due to the intraperitoneal amino acids.
In one small controlled study, Renzo treated four diabetic
CAPD patients with one exchange per day of 1% intraperitoneal
amino acids for 9 to 17 months [19]. A similar group of four
diabetic patients served as controls. All patients initially had low
serum albumin concentrations. After treatment for an average of
12 months, the serum albumin rose significantly, by 0.7 g/dl, in the
amino acid treated group and did not change in the controls.
Moreover, the insulin dosage decreased only in the amino acid
treatment group. In a study by Dombros et al, the intraperitoneal
Fig. 3. Arterialized venous blood pH and pCO2
in seven CAPD patients at the indicated time
points during the study. Brackets indicate the
mean value plus one standard deviation.
amino acids were given in the overnight exchange with no
apparent beneficial effects [17]. The lack of a concurrent intake of
calorie sources and other nutrients might have impaired the
anabolic effects of the intraperitoneal amino acids in these
patients.
The use of amino acids as a substitute for dextrose has been
proposed as a method for reducing hyperlipidemia in chronic
dialysis patients by decreasing the glucose load [27].The replace-
ment of glucose with amino acids in one or at most two dialysate
solutions would be expected to decrease glucose absorption by
only about 20 to 40 g/day of anhydrous D-glucose [28]. This
estimate assumes that the 1.1% amino acid solution is substituted
for 1.5% dextrose (1.36% anhydrous glucose), which has a similar
tonicity. Moreover, the dextrose solution would be expected to
elicit a hyperinsulinemic response and this might also diminish
with an amino acid exchange, thereby reducing lipogenesis and
serum lipid concentrations. However, many of the intraperitoneal
amino acids absorbed may be converted to glucose and also may
stimulate insulin secretion.
Published experience with the dialysate amino acid solutions
indicates that serum lipids generally do not fall significantly [12,
13, 17—19]. Two studies report a decrease in serum cholesterol [14,
15]. One of these reports also described a fall in serum triglycer-
ides [14], whereas in another study, the serum triglycerides rose
[13]. In the present study, serum total cholesterol, HDL choles-
terol, LDL cholesterol and apolipoprotein B did not change with
the intraperitoneal amino acid treatment, although serum triglyc-
erides rose significantly (Table 2). The cause for the rise in serum
triglycerides is unclear. The patients' dietary protein intake during
the study was similar to their prestudy intake (Tables 1 and 3).
However, despite our efforts to design an intake similar to the
prestudy diet, the energy intake during the study may have been
greater. If it was, this could account for the rise in serum
triglycerides, which appeared to have begun during the Baseline
Phase (Table 2).
In the current study, patients appeared to develop a mild
metabolic acidosis when they were given intraperitoneal amino
acids (Table 2, Fig. 3). This was evidenced by a decrease in serum
carbon dioxide combining power and in the arterialized venous
blood pH and pCO2. The anion gap rose slightly with the
intraperitoneal amino acids, from 12.8 to 14.2 mEqlliter, although
the rise was slightly less if serum potassium concentrations were
included in the calculations (that is, from 17.0 to 18.1 mEq/liter).
The fall in serum carbon dioxide combining power also was partly
due to a rise in serum chloride, from 95 to 98 mEqlliter. The
acidemia was greater with two amino acid exchanges than with
one exchange. Other researchers have also described the devel-
opment of mild acidemia with intraperitoneal amino acids [14, 15,
18]. They have attributed the acidemia to the acid load delivered
by the hydrochloride salts of certain basic amino acids as well as
to an increase in the anion gap caused by the metabolism of the
absorbed amino acids.
In the present study, the hydrochloride salt of lysine was
employed in the dialysate containing amino acids. The finding that
there was a slight increase in both the serum chloride and anion
gap suggests that both the hydrochloride salt of lysine and the
generation of acids from the amino acids contributed to the
acidemia. The largest component of the increment in the anion
gap was probably due to sulfate formed by the oxidation of the
sulfur in dialysate methionine. Since even mild degrees of aci-
demia may promote protein catabolism [29], it is important to
prevent the acidemia. This may be possible to achieve by giving
patients small amounts of alkalinizing agents to ingest. In the future
it should be possible to increase the lactate and reduce the chloride
concentrations in the dialysate. It is possible that the anabolic
response to intraperitoneal amino acids in our patients would have
been even greater if the patients had not become acidemic.
Some, but not all studies, indicate that intraperitoneal amino
acids increase peritoneal protein losses [14, 16, 30, 31]. In the
present study no significant increase in peritoneal protein losses
was observed over the 20 days that patients received the amino
acids (data not shown).
Several postabsorptive (overnight fasting) plasma amino acid
levels became more normal with the intraperitoneal amino acid
treatment (Table 3). This was particularly evident for histidine,
lysine, threonine, valine, total essential amino acids, alanine and
I0.
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arginine. Almost all of the changes in plasma amino acids that
occurred with the intraperitoneal amino acids were present by the
tenth day of treatment (day 26). This is not surprising since in
protein depleted non-uremic individuals ingesting low protein
diets, low plasma amino acid concentrations generally rise within
several days in response to a high protein diet [32]. With the
intraperitoneal amino acid treatment, there was an increment in
the preexchange fasting plasma cystine levels, which were not low
during Baseline. This may have been caused by the load of the
cystine precursor, methionine, in the dialysate. In the current
study, postabsorptive plasma methionine levels were normal
(Table 3), although the postexchange plasma methionine was
slightly elevated (data not shown).
The finding that postabsorptive cystine also rose during the
Treatment Phase suggests that the dialysate methionine concen-
trations possibly should be reduced further. On the other hand,
the finding that plasma taurine fell and plasma cysteine rose
during treatment also raises the possibility of a metabolic block in
the synthesis of taurine from cystine. The fall in plasma taurine
during intraperitoneal amino acid treatment is puzzling. Although
the mean plasma taurine levels during the intraperitoneal amino
acid treatment were within the normal range (Table 3), plasma
taurine concentrations in some patients were clearly low. Con-
tamination of plasma with platelets may raise plasma taurine
concentrations [33]. It is possible that this contributed to the
higher taurine levels on day 16, although it is not clear how greater
plasma contamination would occur in all centers on day 16 and
possibly on day 26 (Table 3). The rise in the three urea cycle
amino acids, arginine, citrulline and ornithine, may reflect the
larger amino acid load and, hence, augmented urea generation
during the intraperitoneal amino acid treatment.
In summary, the present study indicates that one or two
peritoneal dialysate exchanges per day containing a 1.1% solution
of essential and nonessential amino acids induced a clear anabolic
response in a group of malnourished CAPD patients who were
ingesting rather low amounts of protein. The intraperitoneal
amino acids were usually well tolerated, although a mild meta-
bolic acidemia, which should be readily treatable, occurred in
some individuals.
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